PFO
WVE icon

Pathstone Family Office’s Wave Life Sciences WVE Stock Holding History

Pathstone Family Office’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$16K – 1360
2020
Q4 		$16K Buy
+2,000
New +$16.8K ﹤0.01% 767

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pathstone Family Office's WVE Position: Q1 2021 in Review

Pathstone Family Office sold out of Wave Life Sciences (WVE) in Q1 2021, closing a stake of 2,000 shares — an estimated $16K sold.

Pathstone Family Office first reported a position in WVE in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 102 funds tracked by Wall St. Rank hold WVE as of Q1 2021.

  • Pathstone Family Office reported no remaining Wave Life Sciences position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 2,000 Wave Life Sciences shares in Q1 2021, an estimated $16K.
  • Pathstone Family Office first reported a position in Wave Life Sciences in Q4 2020 and held it in 1 quarter.
  • Pathstone Family Office's Wave Life Sciences position peaked at $16K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.